Debiopharm Group in-licenses promising biologics and small molecule drug candidates, conducts clinical development, and then out-licenses the products to large pharmaceutical partners for sales and marketing. They have successfully developed and licensed out two compounds, Triptorelin and Oxaliplatin, and are actively seeking partnerships with universities and biotech start-ups to further develop interesting molecules in early-stage research. Debiopharm Group is a Swiss-headquartered global biopharmaceutical group comprising five companies in the life sciences sector.